Reamberin
Phase 3Small molecule
Reamberin is one of 23 small molecule programs targeting COVID-19. It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1Reamberin
PPOLYSAN Scientific & Technological Pharmaceutical Company
Phase 3
Blood Taken
HHospices Civils de Lyon
Preclinical
Other Tkis
BayerPreclinical
Serology
UUniversity Hospital Center of Martinique
Preclinical
Pfizer-Biontech COVID-19 MRNA Vaccine
PfizerPreclinical
Huashi Baidu Granule
XXiyuan Hospital of China Academy of Chinese Medical Sciences
Preclinical
Administration of Almitrine
CCentre Hospitalier Universitaire de Nice
Preclinical
Tpa
UUniversity of Florida
Preclinical
Thrombolytic
FFaculty Hospital Kralovske Vinohrady
Preclinical
Coronavac COVID-19 Vaccine
HHospital Moinhos de Vento
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Ketoacidosis1 trial
REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis
Recruiting·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 2/3·NCT06955416·312 enrolled
Efficacy and Safety1 trial
COVID-191 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Reamberin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details